Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Health Times.
Press releases published on May 19, 2025
Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale
GlobeNewswire
·
May 19, 2025
Regeneron Commits to Comply with Company’s Privacy Policy and All Applicable Law; No Changes to 23andMe’s Privacy Policy or Consumer Genome Services Transaction Subject to Court Approval SAN FRANCISCO, May 19, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. …
Medical Learning Institute Inc Launches reelCE™, a Social-First Approach to Earning Continuing Education Credit
GlobeNewswire
·
May 19, 2025
SAN FRANCISCO, May 19, 2025 (GLOBE NEWSWIRE) -- Medical Learning Institute Inc (MLI), a non-profit jointly accredited continuing education (CE) provider, today announced the launch of reelCE™, enabling busy healthcare providers to earn CE credits by …
Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes
GlobeNewswire
·
May 19, 2025
First-in-human study will evaluate safety, tolerability, and early efficacy of a one-time, pancreas-targeted smart GLP-1TM gene therapy for patients with inadequately controlled T2D and obesity Expect to dose first patients and report preliminary data in …
Dentsply Sirona to Participate in the 2025 Stifel Jaws & Paws Conference
GlobeNewswire
·
May 19, 2025
CHARLOTTE, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the 2025 Stifel Jaws …
XORTX Announces USD $3 Million Offering
GlobeNewswire
·
May 19, 2025
CALGARY, Alberta, May 19, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive …
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
GlobeNewswire
·
May 19, 2025
LONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA …
Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses
GlobeNewswire
·
May 19, 2025
ZUG, Switzerland, May 19, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such …
Teleflex Publishes 2024 Global Impact Report
GlobeNewswire
·
May 19, 2025
WAYNE, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2024 Global Impact Report. The report outlines recent accomplishments and future plans …
Rejuvenate Biomed Doses First Patient in Phase 2 Trial on COPD-related Muscle Weakness and Sarcopenia
GlobeNewswire
·
May 19, 2025
DIEPENBEEK, Belgium, May 19, 2025 (GLOBE NEWSWIRE) -- Rejuvenate Biomed, an AI-enabled, clinical-stage biotech company developing safe, synergistic combination therapeutics that alter the course of age-related diseases, announced today that the first …
Lifeward to Present at Sidoti Virtual Investor Conference on May 21
GlobeNewswire
·
May 19, 2025
MARLBOROUGH, Mass., and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward, Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or …
Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab
GlobeNewswire
·
May 19, 2025
SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced a formulation …
Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
GlobeNewswire
·
May 19, 2025
TEL AVIV, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it has commenced tender offers (the “Offers”) to purchase for cash for a combined aggregate purchase price (exclusive …
Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
GlobeNewswire
·
May 19, 2025
TEL AVIV, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue $2,000,000,000 (equivalent) of senior notes through its special purpose finance subsidiaries. Teva …
Philips launches real-time 3D intracardiac imaging in Europe, expanding access to minimally invasive heart procedures
GlobeNewswire
·
May 19, 2025
May 19, 2025 VeriSight Pro 3D ICE catheter is a pioneering innovation — a miniaturized ultrasound probe embedded at the tip of a thin, steerable catheter, navigated through the vascular system into the heart chambers to deliver high-quality 2D and 3D …
LIfT BioSciences presents latest data on its first-in-class Immunomodulatory Alpha Neutrophils at International Society for Cell and Gene Therapy
GlobeNewswire
·
May 19, 2025
LIfT BioSciences presents latest data on its first-in-class Immunomodulatory Alpha Neutrophils at International Society for Cell and Gene Therapy London, 19 May 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global …
AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection
GlobeNewswire
·
May 19, 2025
PRESS RELEASE AB SCIENCE RECEIVES CHINESE PATENT PROTECTING MASITINIB IN THE TREATMENT OF COVID-19 UNTIL 2041, ADDING ONE MORE INDICATION WITH LONG TERM INTELLECTUAL PROPERTY PROTECTION Paris, May 19, 2025, 8am CET AB Science SA (Euronext - FR0010557264 - …
AB Science reçoit un brevet chinois protégeant le masitinib dans le traitement du Covid-19 jusqu’en 2041, ajoutant ainsi une indication supplémentaire bénéficiant d’une protection à long terme de la propriété intellectuelle
GlobeNewswire
·
May 19, 2025
COMMUNIQUÉ DE PRESSE AB SCIENCE REÇOIT UN BREVET CHINOIS PROTÉGEANT LE MASITINIB DANS LE TRAITEMENT DU COVID-19 JUSQU'EN 2041, AJOUTANT AINSI UNE INDICATION SUPPLÉMENTAIRE BÉNÉFICIANT D'UNE PROTECTION À LONG TERME DE LA PROPRIÉTÉ INTELLECTUELLE Paris, 19 …